Physician profile
Sharon Mccloskey
NPI 1023018215
$3,097.21
in general payments reported to CMS, 2019-2025
33 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $118 · 2021: $398 · 2022: $512 · 2023: $691 · 2024: $535 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,545.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $392.99 | 2019-2025 | |
| Abbvie INC. | $354.83 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $310.45 | 2021-2025 | |
| Hologic Sales and Service, LLC | $235.88 | 2019-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Astellas Pharma US INC | $176.46 | 2021-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $174.69 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $154.08 | 2019-2023 | |
| Therapeuticsmd, INC. | $138.23 | 2019-2021 | |
| Medtronic, INC. | $127.47 | 2022-2023 | V-Loc 180, Closurefast |
| Biogen, INC. | $109.49 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $88.32 | 2021-2022 | |
| Organon LLC | $86.66 | 2022-2025 | Jada System |
| Amag Pharmaceuticals, INC. | $82.35 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $69.46 | 2021 | |
| Exeltis, USA INC. | $63.11 | 2024-2025 | Slynd |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $62.69 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Merck Sharp & Dohme LLC | $52.78 | 2021 | |
| Avion Pharmaceuticals | $51.75 | 2021-2023 | Balcoltra |
| Coopersurgical, INC. | $41.34 | 2022-2023 | Paragard T 380a |
| Exact Sciences Corporation | $38.91 | 2024 | Cologuard Collection Kit |
| Vertical Pharmaceuticals, LLC | $34.30 | 2019 | |
| Allergan, INC. | $30.73 | 2019 | |
| Lupin INC. | $28.26 | 2020-2021 | |
| Becton, Dickinson and Company | $27.18 | 2023 | Bd Max System, Bd Max Instrument |
| Shield Therapeutics INC | $26.67 | 2022-2023 | Accrufer |
| Innovation Technologies INC | $26.55 | 2024 | Irrisept |
| Gynesonics, INC. | $22.88 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Evofem Biosciences, INC. | $17.96 | 2022 | |
| Mylan Pharmaceuticals INC. | $17.88 | 2019 | |
| Dexcom, INC. | $14.60 | 2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $14.02 | 2023 | Quviviq |
| Ibsa Pharma INC. | $13.11 | 2022 | |
| Minerva Surgical, INC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Mccloskey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.